BiotechTube

Hydroxychloroquine + Placebo

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction, Acute Coronary Syndrome, Inflammation, Hydroxychloroquine, Antirheumatic Agents, Cardiovascular Diseases

Trial Timeline

Feb 1, 2016 → Dec 31, 2019

NCT ID
NCT02648464

About Hydroxychloroquine + Placebo

Hydroxychloroquine + Placebo is a approved stage product being developed by Orion Corporation for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT02648464. Target conditions include Myocardial Infarction, Acute Coronary Syndrome, Inflammation.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02648464ApprovedCompleted

Competing Products

20 competing products in Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
76
AbciximabEli LillyApproved
85
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
77
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
52
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
23
No interventionAstellas PharmaPre-clinical
23
Empagliflozin + PlaceboEli LillyPhase 3
77
Abciximab + Abciximab placeboEli LillyPhase 3
77
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
77
AbciximabEli LillyApproved
85
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
77
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
77
abciximabEli LillyApproved
85
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
65
Thrombolytic therapyEli LillyPre-clinical
23
TicagrelorAstraZenecaPre-clinical
23
TicagrelorAstraZenecaPhase 2
52
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
23
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
33
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
77

Other Products from Orion Corporation

Levosimendan + PlaceboApproved
82
MethotrexateApproved
82
DexmedetomidineApproved
82
Levosimendan + PlaceboApproved
82
Polyethylene glycol 4000 + Polyethylene glycol 4000 with electrolytesApproved
82